Skip to main content

Advertisement

Table 6 TSQM domain and global scores: ANCOVA analyses

From: The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis

TSQM scale ANOVA ANCOVAa
LS meanb 95 % CI p valuec LS meanb 95 % CI p valuec
Effectiveness
 CF 65.2 59.9, 70.5   65.0 59.6, 70.5  
 CDMF 66.1 62.5, 69.8   66.2 62.5, 70.0  
 Difference −0.9 −7.4, 5.5 0.776 −1.2 −7.9, 5.4 0.720
Convenience
 CF 94.4 90.6, 98.3   94.8 90.9, 98.6  
 CDMF 86.8 84.2, 89.4   86.7 84.1, 89.3  
 Difference 7.6 3.0, 12.3 0.001 8.1 3.4, 12.8 <0.001
Side effects
 CF 91.6 85.6, 97.5   91.3 85.3, 97.3  
 CDMF 81.6 77.8, 85.5   81.8 77.9, 85.6  
 Difference 10.0 2.8, 17.1 0.007 9.5 2.3, 16.8 0.010
Global
 CF 76.0 70.2, 81.8   75.5 69.7, 81.4  
 CDMF 68.8 64.8, 72.8   69.0 65.0, 73.0  
 Difference 7.2 0.1, 14.2 0.047 6.5 −0.6, 13.7 0.076
  1. aCovariates: age (continuous), gender (male/female), and Total MSRS-R score (continuous)
  2. bHigher scores indicate higher treatment satisfaction (greater perceived effectiveness, greater satisfaction, fewer/less severe side effects, greater global satisfaction)
  3. cp values are provided as descriptive statistics to assess the degree of difference between each LS mean estimate and zero